Cargando…
A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters
Children are at risk of infection from severe acute respiratory syndrome coronavirus-2 virus (SARS-CoV-2) resulting in coronavirus disease (COVID-19) and its more severe forms. New-born infants are expected to receive short-term protection from passively transferred maternal antibodies from their mo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965573/ https://www.ncbi.nlm.nih.gov/pubmed/36851133 http://dx.doi.org/10.3390/vaccines11020255 |
_version_ | 1784896798390747136 |
---|---|
author | Mehla, Rajeev Kokate, Prasad Bhosale, Sarika R. Vaidya, Vivek Narayanan, Shridhar Shandil, Radha. K. Singh, Mayas Rudramurthy, Gudepalya R. Naveenkumar, Chakenahalli N. Bharathkumar, Kumaraswamy Coleman, Rob Mueller, Steffen Dhere, Rajeev M. Yeolekar, Leena R. |
author_facet | Mehla, Rajeev Kokate, Prasad Bhosale, Sarika R. Vaidya, Vivek Narayanan, Shridhar Shandil, Radha. K. Singh, Mayas Rudramurthy, Gudepalya R. Naveenkumar, Chakenahalli N. Bharathkumar, Kumaraswamy Coleman, Rob Mueller, Steffen Dhere, Rajeev M. Yeolekar, Leena R. |
author_sort | Mehla, Rajeev |
collection | PubMed |
description | Children are at risk of infection from severe acute respiratory syndrome coronavirus-2 virus (SARS-CoV-2) resulting in coronavirus disease (COVID-19) and its more severe forms. New-born infants are expected to receive short-term protection from passively transferred maternal antibodies from their mothers who are immunized with first-generation COVID-19 vaccines. Passively transferred antibodies are expected to wane within first 6 months of infant’s life, leaving them vulnerable to COVID-19. Live attenuated vaccines, unlike inactivated or viral-protein-based vaccines, offer broader immune engagement. Given effectiveness of live attenuated vaccines in controlling infectious diseases such as mumps, measles and rubella, we undertook development of a live attenuated COVID-19 vaccine with an aim to vaccinate children beyond 6 months of age. An attenuated vaccine candidate (dCoV), engineered to express sub-optimal codons and deleted polybasic furin cleavage sites in the spike protein of the SARS-CoV-2 WA/1 strain, was developed and tested in hamsters. Hamsters immunized with dCoV via intranasal or intramuscular routes induced high levels of neutralizing antibodies and exhibited complete protection against the SARS-CoV-2 wild-type isolates, i.e., the Wuhan-like (USA-WA1/2020) and Delta variants (B.1.617.2) in a challenge study. In addition, the dCoV formulated with the marketed measles–rubella (MR) vaccine, designated as MR-dCoV, administered to hamsters via intramuscular route, also protected against both SARS-CoV-2 challenges, and dCoV did not interfere with the MR vaccine-mediated immune response. The safety and efficacy of the dCoV and the MR-dCoV against both variants of SARS-CoV-2 opens the possibility of early immunization in children without an additional injection. |
format | Online Article Text |
id | pubmed-9965573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99655732023-02-26 A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters Mehla, Rajeev Kokate, Prasad Bhosale, Sarika R. Vaidya, Vivek Narayanan, Shridhar Shandil, Radha. K. Singh, Mayas Rudramurthy, Gudepalya R. Naveenkumar, Chakenahalli N. Bharathkumar, Kumaraswamy Coleman, Rob Mueller, Steffen Dhere, Rajeev M. Yeolekar, Leena R. Vaccines (Basel) Article Children are at risk of infection from severe acute respiratory syndrome coronavirus-2 virus (SARS-CoV-2) resulting in coronavirus disease (COVID-19) and its more severe forms. New-born infants are expected to receive short-term protection from passively transferred maternal antibodies from their mothers who are immunized with first-generation COVID-19 vaccines. Passively transferred antibodies are expected to wane within first 6 months of infant’s life, leaving them vulnerable to COVID-19. Live attenuated vaccines, unlike inactivated or viral-protein-based vaccines, offer broader immune engagement. Given effectiveness of live attenuated vaccines in controlling infectious diseases such as mumps, measles and rubella, we undertook development of a live attenuated COVID-19 vaccine with an aim to vaccinate children beyond 6 months of age. An attenuated vaccine candidate (dCoV), engineered to express sub-optimal codons and deleted polybasic furin cleavage sites in the spike protein of the SARS-CoV-2 WA/1 strain, was developed and tested in hamsters. Hamsters immunized with dCoV via intranasal or intramuscular routes induced high levels of neutralizing antibodies and exhibited complete protection against the SARS-CoV-2 wild-type isolates, i.e., the Wuhan-like (USA-WA1/2020) and Delta variants (B.1.617.2) in a challenge study. In addition, the dCoV formulated with the marketed measles–rubella (MR) vaccine, designated as MR-dCoV, administered to hamsters via intramuscular route, also protected against both SARS-CoV-2 challenges, and dCoV did not interfere with the MR vaccine-mediated immune response. The safety and efficacy of the dCoV and the MR-dCoV against both variants of SARS-CoV-2 opens the possibility of early immunization in children without an additional injection. MDPI 2023-01-24 /pmc/articles/PMC9965573/ /pubmed/36851133 http://dx.doi.org/10.3390/vaccines11020255 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mehla, Rajeev Kokate, Prasad Bhosale, Sarika R. Vaidya, Vivek Narayanan, Shridhar Shandil, Radha. K. Singh, Mayas Rudramurthy, Gudepalya R. Naveenkumar, Chakenahalli N. Bharathkumar, Kumaraswamy Coleman, Rob Mueller, Steffen Dhere, Rajeev M. Yeolekar, Leena R. A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters |
title | A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters |
title_full | A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters |
title_fullStr | A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters |
title_full_unstemmed | A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters |
title_short | A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters |
title_sort | live attenuated covid-19 candidate vaccine for children: protection against sars-cov-2 challenge in hamsters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965573/ https://www.ncbi.nlm.nih.gov/pubmed/36851133 http://dx.doi.org/10.3390/vaccines11020255 |
work_keys_str_mv | AT mehlarajeev aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT kokateprasad aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT bhosalesarikar aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT vaidyavivek aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT narayananshridhar aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT shandilradhak aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT singhmayas aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT rudramurthygudepalyar aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT naveenkumarchakenahallin aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT bharathkumarkumaraswamy aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT colemanrob aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT muellersteffen aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT dhererajeevm aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT yeolekarleenar aliveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT mehlarajeev liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT kokateprasad liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT bhosalesarikar liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT vaidyavivek liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT narayananshridhar liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT shandilradhak liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT singhmayas liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT rudramurthygudepalyar liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT naveenkumarchakenahallin liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT bharathkumarkumaraswamy liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT colemanrob liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT muellersteffen liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT dhererajeevm liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters AT yeolekarleenar liveattenuatedcovid19candidatevaccineforchildrenprotectionagainstsarscov2challengeinhamsters |